News
Academy
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in Medicine
Conference CoverageConference Listing
Pharmaceutical Executive
Partner Perspectives
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers
Subscribe
Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
Spotlight -
  • Latest Executive Roundtables
  • Asembia 2025
  • Sales Effectiveness
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Academy
    • Partner Perspectives
    • Subscribe
Advertisement

News

Article

September 26, 2023

FDA Releases Draft Guidance for Regulatory Considerations for Prescription Drug-Use-Related Software

The agency differentiates between software that has a notable impact on the effectiveness and safety of drug use.

Pharmaceutical companies are embracing new technologies that could potentially assist patients with taking medication in a safe and effective manner.

In 2018, FDA began soliciting comments for a possible regulatory framework based around these technologies. In September 2023, the agency issued its draft guidance on the subject, explaining how drug sponsors should describe their software both in FDA required labeling and promotional labeling.

For the required labeling, which includes prescribing information, the sponsor can submit evidence to FDA that the software results in a meaningful improvement in a clinical outcome as compared to when the patient takes the drug without using the software. If the evidence supports this, the label should include relevant information about the software and its use.

If the software does not have a meaningful outcome on the use of the medication, then it should not be included on required labeling. In that case, the sponsor will simply have to follow the regulations for promotional labeling and ensure that the information presented, such as in a screen display or text message, is accurate, non-misleading, and balanced.

FDA recognizes various types of software as being prescription drug-use related. This can include apps that act as a digital medication log, or a device-connected product that directly transmits drug use related data.

According to a press release from FDA, the agency has mostly seen products that use basic software that mostly focus on providing convenience to the patient. However, the agency also recognizes that this is a growing field and that more and more drug sponsors are adding software functions to prescription drugs and treatments.

As the field continues to grow, the agency will continue to monitor it and work with companies to ensure that the regulations properly protect products being brought to market.

Source

(Sept. 18, 2023); FDA; Software Associated with Prescription Drugs: Opportunities to Enhance Safe and Effective Medication Use; https://www.fda.gov/drugs/news-events-human-drugs/software-associated-prescription-drugs-opportunities-enhance-safe-and-effective-medication-use

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!
Related Videos
Related Content
Advertisement
Credit: Tada Images | stock.adobe.com, The FDA has authorized the use of updated COVID-19 vaccines for the upcoming fall season, with eligibility limited to adults aged 65 years and older as well as individuals who have at least one underlying medical condition that places them with a high risk for severe COVID-19
August 28th 2025

FDA Authorizes New COVID Vaccines with Restrictions on Eligibility

Davy James
Peter Ax, UpScriptHealth
August 28th 2025

Tariffs and Drug Prices: Understanding the Impact on Pharmaceuticals

Miranda Schmalfuhs
FDA Approves Ionis Pharmaceuticals’ Dawnzera for Hereditary Angioedema
August 28th 2025

FDA Approves Ionis Pharmaceuticals’ Dawnzera for Hereditary Angioedema

Don Tracy, Associate Editor
Navigating Distrust: Pharma in the Age of Social Media
August 28th 2025

Navigating Distrust: Pharma in the Age of Social Media

Miranda Schmalfuhs
Alan Crowther
August 28th 2025

What the Most Favored Nation Executive Order Means to Pharma Brands and Future Implications

Mike Hollan
Lawsuits Likely as Federal Authorities Roll Back Longstanding Vaccine Guidelines
August 28th 2025

Lawsuits Likely as Federal Authorities Roll Back Longstanding Vaccine Guidelines

Don Tracy, Associate Editor
Related Content
Advertisement
Credit: Tada Images | stock.adobe.com, The FDA has authorized the use of updated COVID-19 vaccines for the upcoming fall season, with eligibility limited to adults aged 65 years and older as well as individuals who have at least one underlying medical condition that places them with a high risk for severe COVID-19
August 28th 2025

FDA Authorizes New COVID Vaccines with Restrictions on Eligibility

Davy James
Peter Ax, UpScriptHealth
August 28th 2025

Tariffs and Drug Prices: Understanding the Impact on Pharmaceuticals

Miranda Schmalfuhs
FDA Approves Ionis Pharmaceuticals’ Dawnzera for Hereditary Angioedema
August 28th 2025

FDA Approves Ionis Pharmaceuticals’ Dawnzera for Hereditary Angioedema

Don Tracy, Associate Editor
Navigating Distrust: Pharma in the Age of Social Media
August 28th 2025

Navigating Distrust: Pharma in the Age of Social Media

Miranda Schmalfuhs
Alan Crowther
August 28th 2025

What the Most Favored Nation Executive Order Means to Pharma Brands and Future Implications

Mike Hollan
Lawsuits Likely as Federal Authorities Roll Back Longstanding Vaccine Guidelines
August 28th 2025

Lawsuits Likely as Federal Authorities Roll Back Longstanding Vaccine Guidelines

Don Tracy, Associate Editor
About
Advertise
Contact Us
Editorial Board
Editorial Submission Guidelines
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.